Table 2 Summary of the current management of IL-1 mediated SAIDs
SAIDs | current management | Recommendation Index |
|---|---|---|
MKD | canakinumab | Recommendation A, approved by the FDA, strong evidence for the effectiveness [10, 11] |
anakinra | Recommendation B, canakinumab is unavailable [9] | |
tocilizumab | Recommendation C, IL-1 blockade fails or is unavailable [13] | |
etanercept | Recommendation C, IL-1 blockade fails or is unavailable [12] | |
NSAIDS or glucocorticoids | Recommendation D, mildly affected patients | |
allogeneic stem cell transplantation | Severest cases [17] | |
hemodialysis, kidney transplantation | AA-amyloidosis, kidney failure [15] | |
FMF | Colchicine | Recommendation A, early use after diagnosis [20] |
canakinumab | Recommendation B: the second line: colchicine resistance or intolerance to colchicine, approved by the FDA [23] | |
anakinra | Recommendation C [22] | |
TRAPS | canakinumab | Recommendation A, approved by the FDA [31] |
NSAIDS or glucocorticoids | Mildly affected patients [27] | |
etanercept | Case report [28] | |
anakinra | Case report [29] | |
tocilizumab | Case report [30] | |
hemodialysis, kidney transplantation | AA-amyloidosis, kidney failure [34] | |
PAAND | anakinra | Systemic and/or gastrointestinal inflammation [35] |
adalimumab | Cutaneous and/or articular manifestations [35] | |
isotretinoin | Cutaneous component [35] | |
canakinumab | Systemic and/or gastrointestinal inflammation [35] | |
colchicine and low-dose prednisolone | Case report [36] | |
PAPA | NSAIDS or glucocorticoids | Mildly affected patients [41] |
etanercept, adalimumab and infliximab | Case report [42] | |
anakinra | Case report [41] | |
Canakinumab | Case report [43] | |
retinoids | Case report [41] | |
CAPS | anakinra | Approved by the FDA and EMA [49] |
canakinumab | Approved by the FDA and EMA [52] | |
rilonacept | Approved by the FDA [51] | |
NSAIDS or glucocorticoids | ||
tocilizumab | Case report [55] | |
DIRA | anakinra | |
canakinumab | Case report [62] | |
rilonacept | Case report [61] | |
Majeed syndrome | NSAIDS or glucocorticoids | The first-line [70] |
anakinra | Case report [67] | |
canakinumab | Case report [67] | |
TNF-α blockers or bisphosphonates | Refractory cases [70] | |
NAIAD | corticosteroids | Case report [72] |
acitretin | Case report [71] | |
etanercept or anakinra | Case report [71] | |
NLRC4-MAS | IL-1 blockade | The first-line [74] |
PFIT | hematopoietic stem cell transplantation | Case report [78] |
APIAID | Glucocorticoids | Case report [79] |
IVIG | Case report [79] | |
adalimumab | Case report [79] | |
IL-1 blockers | Case report [84] |